Last reviewed · How we verify
NCT03258190
Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence
Phase 2 trial testing Lime Powder Regimen in Urolithiasis in 137 participants. Completed in 30 June 2018.
1 June 2018
Quick facts
| Lead sponsor | Chulalongkorn University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 137 |
| Start date | 1 July 2014 |
| Primary completion | 1 June 2018 |
| Estimated completion | 30 June 2018 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Lime Powder Regimen — full drug profile →
Conditions studied
- Urolithiasis — all drugs for Urolithiasis →
Sponsor
Chulalongkorn University
Who can join
Adults 18 to 65, any sex, with Urolithiasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lime powder regimen (LPR) is a lime-derived composition enriches with citrate/citric acid and potassium. LPR was invented to treat the renal stone patients with high risk of stone recurrence after stone removal. LPR should have equal or higher efficacy and lower adverse effect than current standard medicine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03258190
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urolithiasis
Currently open trials in the same condition.
- NCT07378904 — Sterile Water Injection vs Morphine for Renal Colic · NA · active not recruiting
- NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease · NA · recruiting
- NCT06651294 — Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments · NA · recruiting
- NCT07514676 — Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Cult · active not recruiting
- NCT06158620 — Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease · Phase 1, PHASE2 · recruiting
Other Chulalongkorn University trials
Trials by the same sponsor.
- NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
- NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
- NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
- NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
- NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03258190 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
- Last refreshed: 1 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03258190.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing